Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajiv Raja

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC StudyHan Si, Michael Kuziora, Katie J Quinn, et al.
Plos One|February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancersErica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPatricia McCoon, Ying Wang, Zhongwu Lai, et al.
The Oncologist|March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencingLiangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Plos One|November 16, 2016
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder CancersDoris Kim, YounJeong Choi, James Ireland, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Weimin Li, Song Wu, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC StudyHan Si, Michael Kuziora, Katie J Quinn, et al.
Plos One|February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancersErica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Plos One|June 8, 2018
Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancerMonika A Jarzabek, William R Proctor, Jennifer Vogt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor OutcomesPatricia McCoon, Ying Wang, Zhongwu Lai, et al.
The Oncologist|March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencingLiangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Plos One|November 16, 2016
Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder CancersDoris Kim, YounJeong Choi, James Ireland, et al.
Plos One|March 8, 2013
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neckDavid S Shames, Juliet Carbon, Kim Walter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Weimin Li, Song Wu, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 4